Tampere, Finland, November 24, 2021—Combinostics, provider of artificial intelligence (AI) technology to help radiologists, clinicians, and researchers make confident, evidence-based decisions for diagnosis, management, and therapeutic development in neurological disorders, today announced the company’s expanding leadership team with the addition of Greg Kingston as Chief Marketing Officer.
“Our recent successes and subsequent growth are a testament to the fact that our products provide a more comprehensive solution than any other product on the market,” said Dr. Richard Hausmann, CEO of Combinostics. “As CMO, Greg brings specific experience in the global marketing of medical imaging software that will enable him to harness this growth and capitalize on these successes, expanding our reach through increased marketing efforts and burgeoning partnerships.”
Greg is an international marketing executive with over a decade of experience in the medical imaging software domain, with a focus on AI-based technology. Prior to joining Combinostics, Greg led marketing initiatives at medical imaging platform provider Blackford Analysis. Previously, Greg held positions at Vital Images and Toshiba Medical Visualization Systems.
“This is a really exciting time to join Combinostics,” said Greg. “With an extremely strong leadership team, scientific expertise, and unmatched technology, Combinostics is poised to have a significant impact on physicians and the patients they treat, particularly when combined with the industry’s advances in treatments for neurodegenerative disorders. I’m honored to be a part of this talented team and to further the Combinostics mission to support clinicians and researchers as they work to improve the lives of patients with neurological disorders.”
Through its cloud-based cNeuro® suite of products, Combinostics supports clinicians and researchers with innovative clinical decision support solutions that help make sense of the overwhelming amount of data for patients with neurological disorders, in a single location and in the context of previous patient diagnoses. Applications within the cNeuro suite provide objective, systematic, quantifiable insights into neurological disorders such as Alzheimer’s disease and multiple sclerosis as well as traumatic brain injuries.
For more information or to view a demo of the entire cNeuro suite, including applications in development, join the leadership team at booth #4937 in the AI showcase at RSNA 2021 in Chicago, November 28 to December 2, 2021. Schedule an in-person or virtual meeting at www.combinostics.com/RSNA.
About Combinostics
Combinostics’ AI-powered cNeuro® suite of products helps clinicians make a difference in the lives of patients with neurological disorders. By quantifying brain images and integrating patient data from multiple sources with insights from previous patients, the company’s unique software tools provide radiologists and clinicians the support they need for confident, evidence-based diagnostic and management decisions. The company was founded in 2014 and is headquartered in Tampere, Finland. For more information, please visit www.combinostics.com.
